Selexis CHO Cells in Suspension-1

Archives 2015

Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades. 

DECEMBER 14, 2015
2 min read

Complix Advances Novel Biospecific ImmunotherapeuticCMX-02 - Enters Agreement with Selexis to Access SUREtechnology Platform

Hasselt, Belgium, December 14, 2015 – Complix NV, a biopharmaceutical company developing a pipeline of transformative...

Read More
NOVEMBER 5, 2015
5 min read

Agenus to Acquire Antibody Manufacturing Capability, Expands Antibody Discovery and adds Cell Line Development Capabilities with Three Separate Transactions

  • To acquire biologics manufacturing facility and capabilities from XOMA
  • Acquires rights to Selexis cell line development...
  • Read More
    NOVEMBER 3, 2015
    2 min read

    Faron Enters Agreement with Selexis SA to Progress Development of Novel Cancer Immunotherapy Clevegen

    TURKU - FINLAND 03 November 2015 – Faron Pharmaceuticals Oy (”Faron”), the clinical stage biopharmaceutical company,...

    Read More
    SEPTEMBER 22, 2015
    1 min read

    Selexis SA Announces Service Agreement with Swedish Orphan Biovitrum AB (Sobi)

    Selexis Will Apply the SURE CHO-Mplus Libraries™ to Achieve OptimalExpression Results with a Difficult-to-Express...

    Read More
    MAY 20, 2015
    2 min read

    Merus and Selexis Receive a €2.1 Million Grant for Single-Cell-Line Manufacturing of a Bispecific Antibody Combination to Treat Colorectal Cancer

    Geneva, Switzerland, May 20, 2015 -- Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics...

    Read More
    JANUARY 22, 2015
    1 min read

    Selexis-Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing

    Selexis SA is the First biotechnology Company to Deliver Manufacturing-ReadyResearch Cell Banks with a Fully Sequenced...

    Read More
    JANUARY 8, 2015
    1 min read

    First Selexis SUREtechnology-Generated Therapeutic Monoclonal Antibody Approved for Market

    Geneva, Switzerland, January 8, 2015 – Selexis SA, a serial innovation company with proven technologies for...

    Read More